ReviewFuture science OA2025
Prognostic value of systemic inflammation response index in cervical cancer: a meta-analysis.
Review in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of systemic inflammatory response index in patients with bladder cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Value of different nutritional and inflammatory markers for diagnosis of peritonitis in patients undergoing peritoneal dialysis.Renal failure · 2026Article
- Baseline inflammatory and metabolic indicators associated with early PD-1 inhibitor resistance in advanced cervical cancer: a retrospective cohort study.Frontiers in medicine · 2026Article
- Study on risk stratification and treatment strategy of blood indicators in patients with moderate risk of GIST.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe value of systemic inflammation response index (SIRI) in predicting cervical cancer (CC) prognosis has been evaluated, but the conclusions were debated. By performing a meta-analysis, this study sought to establish the accurate prognostic relevance of SIRI for CC.
methodsThe study aimed to determine the effect of SIRI on predicting CC overall survival (OS) and progression-free survival (PFS) by HRs with 95%CIs.
resultsThis work incorporated seven studies with 1271 patients enrolled. Based on our combined data, elevated SIRI exhibited remarkable relation to dismal OS (HR = 2.58, 95%CI = 1.75-3.79, p < 0.001) and worse PFS (HR = 1.88, 95%CI 1.33-2.66, p < 0.001) in CC. In addition, higher SIRI was significantly associated with advanced FIGO stage (OR = 1.71, 95%CI = 1.18-2.50, p = 0.005) and high-grade histology (OR = 1.63, 95%CI = 1.15-2.32, p = 0.006) of CC. Nonetheless, SIRI was not related to age, lymphovascular invasion (LVSI), tumor size, tumor invasion depth, pathological type, or lymph node (LN) metastasis.
conclusionThis meta-analysis revealed that higher SIRI is significantly related to impaired OS and poor PFS of CC cases. Furthermore, higher SIRI is also significant correlated to advanced FIGO stage and poor tumor differentiation of CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.